Ranbaxy gains pre-qualification for more antiretroviral products

By Elaine Rigoli

Tampa, Fla., May 24 - Ranbaxy Laboratories, Ltd. has announced that the World Health Organization in Geneva has included four additional antiretroviral products of the company in its pre-qualification list, including Efavirenz 600 mg tablets, Efavirenz 200 mg capsules, Stavudine 30 mg capsules and Stavudine 40 mg capsules.

With these inclusions, the company said it now has a total of 12 antiretroviral products on the World Health Organization pre-qualification list.

Ranbaxy also has three approvals from the Food and Drug Administration for antiretroviral products, making it eligible for making supplies to the U.S.-funded Pepfar program.

Ranbaxy, based in Mumbai, India, is an integrated, research-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.